TGF-β mammary gland development and breast cancer

Breast Disease

Volumn 18, Issue , 2003, Pages 61-73

  Serra, Rosa ^a   Crowley, Michael R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BRANCHING MORPHOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER INHIBITION; CANCER PREVENTION; CELL DIFFERENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INVOLUTION; MICROENVIRONMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STROMA CELL; TUMOR SUPPRESSOR GENE;

EID: 4444346007     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2003-18107     Document Type: Review

References (116)

1. A.B. Roberts and M.B. Sporn, The Transforming Growth Factor-bs, in: Peptide Growth Factors and their Receptors, M.B. Sporn and A.B. Roberts, eds, Heidelberg: Springer-Verlag, 1990, pp. 419-472.
2. D.A. Miller, R.W. Pelton, R. Derynck and H.L. Moses, Transforming growth factor-b: A family of growth regulatory peptides, Ann. N. Y. Acad. Sci. 593 (1990), 208-217.
3. J. Massague, S.W. Blain and R.S. Lo, TGFbeta signaling in growth control, cancer, and heritable disorders, Cell 103 (2000), 295-309.
4. H.L. Moses, E.B. Branum, J.A. Proper and R.A. Robinson, Transforming growth factor production by chemically transformed cells, Cancer Research 41 (1981), 2842-2848.
5. A.B. Roberts, M.A. Anzano, L.C. Lamb, J.M. Smith and M.B. Sporn, New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non-neoplastic tissues, Proc. Natl. Acad. Sci. USA 78 (1981), 5339-5343.
6. H.L. Moses, E.Y. Yang and J.A. Pietenpol, TGF-b stimulation and inhibition of cell proliferation: New mechanistic insights, Cell 63 (1990), 245-247.
7. R.F. Tucker, G.D. Shipley, H.L. Moses and R.W. Holley, Growth inhibitor from BSC-1 cells closely related to the platelet type beta transforming growth factor, Science 226 (1984), 705-707.
8. D.M. Kingsley, The TGF-b superfamily: New members, new receptors, and new genetic tests of function in different organisms, Genes and Development 8 (1994), 133-146.
9. R. Pircher, P. Jullien and D.A. Lawrence, Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex, Biochemical anal Biophysical Research Communications 136 (1986), 30-37.
10. L.M. Wakefield, D.M. Smith and S. Broz et al., Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex, Growth Factors 1 (1989), 203-218.
11. M.H. Barcellos-Hoff, Latency and activation in the control of TGF-beta, J Mammary Gland Biol Neoplasia 1 (1996), 353-363.
12. J.E. Murphy-Ullrich and M. Poczatek, Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology, Cytokine Growth Factor Rev 11 (2000), 59-69.
13. K. Koli, J. Saharinen, M. Hyytiainen, C. Penttinen and J. Keski-Oja, Latency, activation, and binding proteins of TGF-beta, Microsc Res Tech 52 (2001), 354-362.
14. A.M. Brunner, H. Marquardt, A.R. Malacko, M.N. Lioubin and A.F. Purchio, Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta-1 precursor, J. Biol. Chem. 264 (1989), 13660-13664.
15. R. Oklu and R. Hesketh, The latent transforming growth factor beta binding protein (LTBP) family, Biochem J 352(3) (2000), 601-610.
16. R. Derynck, TGF-b-receptor-mediated signaling, Trends Biochem. Sci. 19 (1994), 548-553.
17. P. Ten Dijke, K. Miyazono and C-H. Heldin, Signaling via hetero-oligomeric complexes of type I and type II serine treonine kinase receptors, Current Opinion in Cell Biology 8 (1996), 139-145.
18. J. Massague, TGF-b signal transduction, Annu. Rev. Biochem. 67 (1998), 753-791.
19. J.L. Wrana, L. Attisano, R. Wieser, F. Ventura and J. Massagué, Mechanism of activation of the TGF-β receptor, Nature 370 (1994), 341-347.
20. R. Derynck and Y. Zhang, Intracellular signaling: The MAD way to do it, Current Biology 6 (1996), 1226-1229.
21. J. Massague, TGF-βsignal transduction, Annual Review of Biochemistry 67 (1998), 753-791.
22. J. Massague and D. Wotton, Transcriptional control by the TGF-beta/Smad signaling system, Embo J 19 (2000), 1745-1754.
23. J.L. Wrana and L. Attisano, The Smad pathway, Cytokine Growth Factor Rev 11 (2000), 5-13.
24. J.J. Sekelsky, S.J. Newfeld, L.A. Raftery, E.H. Chartoff and W.M. Gelbart, Genetic characterization and cloning of Mothers against DPP, a gene required for decapentaplegic function in drosophila melanogaster, Genetics 139 (1995), 1347-1358.
25. C. Savage, P. Das and A.L. Finelli et al., Caenorhabditis elegans genes sma2, sma-3, and sma-4 define a conserved family of transforming growth factor b pathway components, Proc. Natl. Acad. Sci. USA 93 (1996), 790-794.
26. S.A. Hahn, M. Schutte and A.T.M.S. Hoque et al., DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1, Science 271 (1996), 350-353.
27. K. Eppert, S.W. Scherer and H. Ozcelik et al., MADR2 maps to 18q21 and encodes a TGF-b regulated MAD-related protein that is functionally mutated in colorectal carcinoma, Cell 86 (1996), 543-552.
28. Y. Zhang and R. Derynck, Regulation of Smad signalling by protein associations and signalling crosstalk, Trends Cell Biol 9 (1999), 274-279.
29. J. Massague and Y.G. Chen, Controlling TGF-beta signaling, Genes Dev 14 (2000), 627-644.
30. L. Attisano and J.L. Wrana, Smads as transcriptional comodulators, Curr Opin Cell Biol 12 (2000), 235-243.
31. A. Hata, G. Lagna, J. Massague and A. Hemmati-Brivanlou, Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor, Genes Dev 12 (1998), 186-197.
32. H. Hayashi, S. Abdollah and Y. Qiu et al., The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling, Cell 89 (1997), 1165-1173.
33. W. Imagawa, J. Yang, R. Guzman and N. Satybrata, Control of Mammary Gland Development, in: The Physiology of Reproduction, Second Edition, E. Knobil, and J.D. Neil, eds, New York: Raven Press, Ltd. 1994, pp. 1033-1063.
34. L. Hennighausen and G.W. Robinson, Signaling pathways in mammary gland development, Dev Cell 1 (2001), 467-475.
35. G.B. Silberstein, Postnatal mammary gland morphogenesis. Microsc Res Tech 52 (2001), 155-162.
36. C.W. Daniel, S. Robinson and G.B. Silberstein, The transforming growth factors beta in development and functional differentiation of the mouse mammary gland, Adv Exp Med Biol 501 (2001), 61-70.
37. P.P. Osin, R. Anbazhagan, J. Bartkova, B. Nathan and B.A. Gusterson, Breast development gives insights into breast disease, Histopathology 33 (1998), 275-283.
38. S.D. Robinson, G.B. Silberstein, A.B. Roberts, K.C. Flanders and C.W. Daniel, Regulated expression and growth inhibitory effects of transforming growth factor-b isoforms in mouse mammary gland development, Development 113 (1991), 867-878.
39. E. Faure, N. Heisterkamp, J. Groffen and V. Kaartinen, Differential expression of TGF-beta isoforms during postlactational mamary gland involution, Cell Tissue Res 300 (2000), 89-95.
40. A.V. Nguyen and J.W. Pollard, Transforming growth factor beta3 induces cell death during tbe first stage of mammary gland involution, Development 127 (2000), 3107-3118.
41. R. Strange, F. Li, S. Saurer, A. Burkhardt and R.R. Friis, Apoptotic cell death and tissue remodelling during mouse mammary gland involution, Development 115 (1992), 49-58.
42. G.B. Silberstein, K.C. Flanders, A.B. Roberts and C.W. Daniel, Regulation of mammary morphogenesis: Evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-b1, Dev. Biol. 152 (1992), 354-362.
43. C.W. Daniel, S. Robinson and G.B. Silberstein, The role of TGF-beta in patterning and growth of tbe mammary ductal tree, J Mammary Gland Biol Neoplasia 1 (1996), 331-341.
44. K.B. Ewan, G. Shyamala and S.A. Ravani et al., Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation, Am J Pathol 160 (2002), 2081-2093.
45. B.K. McCune, B.R. Mullin and K.C. Flanders et al., Localization of transforming growth factor-b isotypes in lesions of the human breast, Hum. Pathol. 23 (1992), 13-20.
46. H. Gobbi, W.D. Dupont and J.F. Simpson et al., Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia, J Natl Cancer Inst 91 (1999), 2096-2101.
47. H. Joseph, A. Gorska, P. Sohn, H.L. Moses and R. Serra, Overexpression of a kinase-defiecient transforming growth factor-β type II receptor In mouse mammary stroma results in increased epithelial branching, Molecular Biology of the Cell 10 (1999), 1221-1234.
48. Y.A. Yang, B. Tang and G. Robinson et al., Smad3 in the mammary epithelium has a nonredundant role in the induction of apoptosis, but not in the regulation of proliferation or differentiation by transforming growth factor-beta, Cell Growth Differ 13 (2002), 123-130.
49. A.B. Kulkarni, C-G. Huh and D. Becker et al., Transforming growth factor b1 null mutation in mice causes excessive inflammatory response and early death, Proc. Natl. Acad. Sci. USA 90 (1993), 770-774.
50. G.H. Smith, TGF-beta and functional differentiation, J Mammary Gland Biol Neoplasia 1 (1996), 343-352.
51. G.B. Silberstein and C.W. Daniel, Reversible inhibition of mammary gland growth by transforming growth factor-beta, Science 237 (1987), 291-293.
52. D.F. Pierce, Jr., M.D. Johnson and Y. Matsui et al., Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-b1, Genes and Development 7 (1993), 2308-2317.
53. T. Yamamoto, H. Komura and K. Morishige et al., Involvement of autocrine mechanism of transforming growth factor-b in the functional differentiation of pregnant mouse mammary gland, Acta Endocrinol. (Copenh.) 130 (1994), 302-307.
54. S.D. Robinson, A.B. Roberts and C.W. Daniel, TGFb suppresses casein synthesis in mouse mammary explants and may play a role in controlling milk levels during pregnancy, Journal of Cell Biology 120 (1993), 245-251.
55. A.W. Sudlow, C.J. Wilde and R.D. Burgoyne, Transforming growth factor-b1 inhibits casein secretion from differentiating mammary-gland explants but not from lactating mammary cells, Biochem. J. 304 (1994), 333-336.
56. C.W. Daniel, G.B. Silberstein, K. Van Horn, P. Strickland and S. Robinson, TGF-beta 1-induced inhibition of mouse mammary ductal growth: developmental specificity and characterization, Dev. Biol. 135 (1989), 20-30.
57. C. Jhappan, A.G. Geiser and E.C. Kordon et al., Targeting expression of a transforming growth factor b1 transgene to the pregnant mammary gland inhibits alveolar development and lactation, EMBO J. 12 (1993), 1835-1845.
58. E.C. Kordon, R.A. McKnight and C. Jhappan et al., Ectopic TGFb1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population, Dev. Biol. 168 (1995), 47-61.
59. P.M. Siegel, W. Shu, R.D. Cardiff, W.J. Muller and J. Massague, Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis, Proc Natl Acad Sci USA (2003).
60. A.E. Gorska, H. Joseph, R. Derynck, H.L. Moses and R. Serra, Dominant-negative interference of the transforming growth factor beta type II receptor in mammary epithelium results in alveolar hyperplasia and differentiation in virgin mice, Cell Growth and Differentiation 9 (1998), 229-238.
61. E.P. Bottinger, J.L. Jakubczak, D.C. Haines, K. Bagnall and L.M. Wakefield, Transgenic mice overexpressing a dominant-negative mutant type II TGF-b receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz- [a]-anthracene, Cancer Research 57 (1997), 5564-5570.
62. R. Strange, T. Metcalfe, L. Thackray and M. Dang, Apoptosis in normal and neoplastic mammary gland development, Microsc Res Tech 52 (2001), 171-181.
63. W. Li, W. Qiao and L. Chen et al., Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice, Development 130 (2003), 6143-6153.
64. M.G. Alexandrow and H.L. Moses, Transforming growth factor b and cell cycle regulation, Cancer Research 55 (1995), 1452-1457.
65. S. Markowitz, J. Wang and L. Myeroff et al., Inactivation of the type II TGF-b receptor in colon cancer cells with microsatellite instability, Science 268 (1995), 1336-1338.
66. R. Serra and H.L. Moses, Tumor suppressor genes in the TGF-b signaling pathway? Nature Medicine 2 (1996), 390-391.
67. R. Derynck, R.J. Akhurst and A. Balmain, TGF-beta signaling in tumor suppression and cancer progression, Nat Genet 29 (2001), 117-129.
68. B. Tang, E.P. Bottinger and S.B. Jakowlew et al., Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency, Nat Med 4 (1998), 802-807.
69. H. Gobbi, C.L. Atteaga and R.A. Jensen et al., Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas (see comments), Histopathology 36 (2000), 168-177.
70. Y. Matsui, S.A. Halter, J.T. Holt, B.L.M. Hogan and R.J. Coffey, Jr. Development of mammary hyperplasia and neoplasia in MMTV- TGFalpha transgenic mice, Cell 61 (1990), 1147-1156.
71. D.F. Pierce, Jr., A.E. Gorska and A. Chytil et al., Mammary tumor suppression by transforming growth factor b1 transgene expression, Proc. Natl. Acad. Sci. USA 92 (1995), 4254-4258.
72. A.E. Gorska, R.A. Jensen and Y. Shyr et al., Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation, Am J Pathol 163 (2003), 1539-1549.
73. W.J. Muller, E. Sinn, P.K. Pattengale, R. Wallace and P. Leder, Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c- neu oncogene, Cell 54 (1988), 105-115.
74. C.A. Boulanger and G.H. Smith, Reducing mammary cancer risk through premature stem cell senescence, Oncogene 20 (2001), 2264-2272.
75. V. Buggiano, C. Schere-Levy and K. Abe et al., Impairment of mammary lobular development induced by expression of TGFbeta1 under the control of WAP promoter does not suppress tumorigenesis in MMTV-infected transgenic mice, Int J Cancer 92 (2001), 568-576.
76. W. Cui, D.J. Fowlis and S. Bryson et al., TGF-b1 inhibits the formation of benign skin tumors, but enhances the progression to invasive spindle carcinomas in transgenic mice, Cell 86 (1996), 531-542.
77. S.N. Thibodeau, G. Bren and D. Schaid, Microsatellite instability in cancer of the proximal colon, Science 260 (1993), 816-819.
78. M. Oft, K.H. Heider and H. Beug, TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis, Curr Biol 8 (1998), 1243-1252.
79. B.A. Teicher, Malignant cells, directors of the malignant process: role of transforming growth factor-beta, Cancer Metastasis Rev 20 (2001), 133-143.
80. S.M. Sheen-Chen, H.S. Chen, C.W. Sheen, H.L. Eng and W.J. Chen, Serum levels of transforming growth factor beta1 in patients with breast cancer, Arch Surg 136 (2001), 937-940.
81. V. Ivanovic, N. Todorovic-Rakovic and M. Demajo et al., Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression, Eur J Cancer 39 (2003), 454-461.
82. L.M. Wakefield, Y.A. Yang and O. Dukhanina, Transforming growth factor-beta and breast cancer: Lessons learned from genetically altered mouse models, Breast Cancer Res 2 (2000), 100-106.
83. N. Dumont and C.L. Arteaga, Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta, Breast Cancer Res 2 (2000), 125-132.
84. D.R .Welch, A. Fabra and M. Nakajima, Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential, Proc Natl Acad Sci USA 87 (1990), 7678-7682.
85. D. Nakata, J. Hamada and Y. Ba et al., Enhancement of tumorigenic, metastatic and in vitro invasive capacity of rat mammary tumor cells by transforming growth factor-beta, Cancer Lett 175 (2002), 95-106.
86. J.A. McEarchern, J.J. Kobie and V. Mack et al., Invasion and metastasis of a mammary tumor involves TGF-beta signaling, Int J Cancer 91 (2001), 76-82.
87. M. Oft, J. Peli and C. Rudaz et al., TGF-beta1 and HaRas collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells, Genes Dev 10 (1996), 2462-2477.
88. R.S. Muraoka, Y. Koh and L.R. Roebuck et al., Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1, Mol Cell Biol 23 (2003), 8691-8703.
89. S.W. Tabin, K. Douville and U. Benbow et al., Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects, Oncogene 21 (2002), 108-118.
90. S.M. Kakonen and G.R. Mundy, Mechanisms of osteolytic bone metastases in breast carcinoma, Cancer 97 (2003), 834-839.
91. J.J. Yin, K. Selander and J.M. Chirgwin et al., TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development, J Clin Invest 103 (1999), 197-206.
92. S.M. Kakonen, K.S. Selander and J.M. Chirgwin et al., TGF-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways, J Biol Chem 8 (2002), 6.
93. A.E. Broadus and A.F. Stewart, Parathyroid hormone-related protein, in: The Parathyroids, J.P. Bilezikian, M.A. Levine and R. Marcus, eds, New York: Raven Press, Ltd, 1994, pp. 259-294.
94. L.J. Suva, G.A. Winslow and R.E.H. Wettenhall et al., A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression, Science 237 (1987), 893-896.
95. R.J. Akhurst, TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest 109 (2002), 1533-1536.
96. A. Bandyopadhyay, Y. Zhu and M.L. Cibull et al., A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells, Cancer Res 59 (1999), 5041-5046.
97. R.S. Muraoka, N. Dumont and C.A. Ritter et al., Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases, J Clin Invest 109 (2002), 1551-1559.
98. Y.A. Yang, O. Dukhanina and B. Tang et al., Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects, J Clin Invest 109 (2002), 1607-1615.
99. A. Noel and J.M. Foidart, The role of stroma in breast carcinoma growth in vivo, J Mammary Gland Biol Neoplasia 3 (1998), 215-225.
100. A.C. Erickson and M.H. Barcellos-Hoff, The not-so innocent bystander: the microenvironment as a therapeutic target in cancer, Expert Opin Ther Targets 7 (2003), 71-88.
101. J.A. Tuxhorn, G.E. Ayala and D.R. Rowley, Reactive stroma in prostate cancer progression, J Urol 166 (2001), 2472-2483.
102. T.D. Tlsty, Stromal cells can contribute oncogenic signals, Semin Cancer Biol 11 (2001), 97-104.
103. T.D. Tlsty and P.W. Hein, Know thy neighbor: stromal cells can contribute oncogenic signals, Curr Opin Genet Dev 11 (2001), 54-59.
104. B.S. Wiseman and Z. Werb, Stromal effects on mammary gland development and breast cancer, Science 296 (2002), 1046-1049.
105. C.J. Hsieh, B. Klump and K. Holzmann et al., Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis, Cancer Res 58 (1998), 3942-3945.
106. T.W. Jacobs, C. Byrne, G. Colditz, J.L. Connolly and S.J. Schnitt, Radial scars in benign breast-biopsy specimens and the risk of breast cancer (see comments), N Engl J Med 340 (1999), 430-436.
107. R.F. Jacoby, S. Schlack and C.E. Cole et al., A juvenile polyposis tumor suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria, Gastroenterology 112 (1997), 1398-1403.
108. J.R. Howe, S. Roth and J.C. Ringold et al., Mutations in the SMAD4/DPC4 gene in juvenile polyposis (see comments), Science 280 (1998), 1086-1088.
109. F. Moinfar, Y.G. Man and L. Arnould et al., Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis, Cancer Res 60 (2000), 2562-2566.
110. M.D. Sternlicht, M.J. Bissell and Z. Werb, The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter, Oncogene 19 (2000), 1102-1113.
111. L. Ronnov-Jessen, O.W. Petersen and M.J. Bissell, Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction, Physiol Rev 76 (1996), 69-125.
112. N. Hayashi and G.R. Cunha, Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma, Cancer Res 51 (1991), 4924-4930.
113. M.H. Barcellos-Hoff and S.A. Ravani, Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells, Cancer Res 60 (2000), 1254-1260.
114. M.H. Barcellos-Hoff, Radiation-induced transforming growth factor b and subsequent extracellular matrix reorganization in murine mammary gland, Cancer Research 53 (1993), 3880-3886.
115. M.H. Barcellos-Hoff, R. Derynck, M.L.-S. Tsang and J.A. Weatherbee, Transforming growth factor-b activation in irradiated murine mammary gland, J. Clin. Invest. 93 (1994), 892-899
116. E.J. Ehrhart, P. Segarini, M.L. Tsang, A.G. Caroll and M.H. Barcellos-Hoff, Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation, Faseb J 11 (1997), 991-1002.